Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma
2019
Purpose:
Pheochromocytomasand
paragangliomas(PPGL) are rare
neuroendocrine tumors. While most PPGL are benign, up to 20% may become metastatic with
SDHB- and FH -mutated tumors showing the higher risk. We aimed at determining the contribution of
immortalizationmechanisms to metastatic progression. Experimental design:
Immortalizationmechanisms were investigated in 200 tumors. To identify
telomerase(+) tumors we analyzed genomic alterations leading to transcriptional activation of TERT comprising promoter mutations, hypermethylation and gain copy number. To identify tumors that activated the alternative lengthening of telomere (ALT) mechanism, we combined analyses of telomere length by slot blot, telomere heterogeneity by telomere FISH, and
ATRXmutations by next-generation sequencing. Univariate/multivariate and metastasis-free survival (MFS) and overall survival (OS) analyses were carried out for assessment of risk factors and clinical outcomes. Results: Only 37/200 (18.5%) tumors achieved
immortalization.
Telomeraseactivation occurred in 12 metastatic tumors, and was prevalent in
SDHB-mutated
paragangliomas( P = 2.42e-09). ALT features were present in 25 tumors, mostly
pheochromocytomas, regardless of metastatic status or molecular group ( P = .169), yet
ATRXmutations were found preferentially in
SDHB/ FH -mutated metastatic ( P = .0014).
Telomeraseactivation and
ATRXmutations were independent factors of poor prognosis: MFS (
hazard ratio, 48.2 and 33.1; P = 6.50E-07 and 1.90E-07, respectively); OS (
hazard ratio, 97.4 and 44.1; P = 4.30E-03 and 2.00E-03, respectively) and were associated with worse MFS and OS (logrank tests P
ATRXmutations could be used to identify metastatic PPGL, particularly in tumors at high-risk of progression.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
50
References
54
Citations
NaN
KQI